Australia’s Impression Healthcare Limited (ASX:IHL) has acquired CBD inhalers it says will be available for purchase in Australia under the Therapeutic Goods Administration’s (TGA’s) Special Access Scheme (SAS).
We’ve mentioned Impression Healthcare on Hemp Gazette previously when the company made the jump from mouthguards to cannabis (but it still makes mouthguards too)
It was in 2018 when it kicked off its forays into this sector with cannabinoid chewing gum. It’s not clear what happened there as little has been subsequently published about that particular arrangement and a search for the product involved on Impression’s web site turns up zilch.
Since that time IHL has established Incannex Pharmaceuticals, which is developing cannabis oils.
But back to the pressurised metered dose inhalers, aka puffers. Impression says it has placed an initial order of 500 units from the USA’s Entourage Therapeutics, which has also granted IHL exclusivity in Australia for sales of the product.